MSACL 

39. Analysis of Multiple Protein Marker Panels: Optimizing Sensitivity and Selectivity
Poster: Tue 2:00-3:00PM
Michael Athanas
VAST Scientific
M. Athanas, VAST Scientific, Cambridge, MA, USA
A, Prakash, Thermo Fisher Scientific, BRIMS, Cambridge, MA, USA
T. Rezai, Thermo Fisher Scientific, BRIMS, Cambridge, MA, USA
B. Krastins, Thermo Fisher Scientific, BRIMS, Cambridge, MA, USA
D. Sarracino, Thermo Fisher Scientific, BRIMS, Cambridge, MA, USA
Kypros Nicolaides, Fetal Medicine Foundation, London, UK
Ramesh Kuppusamy, Fetal Medicine Foundation, London, UK
Mary F. Lopez, Thermo Fisher Scientific, BRIMS, Cambridge, MA, USA
Proteomic discovery experiments are rapidly generating lists of putative biomarkers for diseases and pathologies. Verification of these markers in multiplexed assays poses a statistical challenge as traditional ROC (Receiver Operation Characteristic) curves used to calculate the sensitivity and specificity of a diagnostic or predictive assay are based on single markers. The ability to combine quantitative information from several markers could potentially improve the diagnostic accuracy of existing tests and facilitate the development of new tests. However, standardized approaches to representing panels of markers remains controversial.

In this analysis, we apply proteomics and mass spectrometry techniques for the discovery of new putative biomarkers for Trisomy 21 in first trimester maternal serum. Maternal serum samples from Trisomy 21 and normal first trimester pregnancies were provided by the Fetal Medicine Foundation and collected from study participants with full consent and approval. High resolution LC-MS/MS analysis was carried out on an LTQ-Orbitrap XL mass spectrometer.
Email: [email protected]